← Back to Search

Tetracycline Antibiotic

Minocycline for Diabetic Kidney Disease

N/A
Waitlist Available
Led By Sharon G Adler, MD
Research Sponsored by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights

Summary

This trial is testing minocycline, an antibiotic, to see if it can safely help people with Type 2 diabetes who have kidney disease. Current treatments can cause serious side effects, so a safer option is needed. Minocycline has shown promise in animal studies by protecting kidney cells from damage.

Eligible Conditions
  • Diabetic Kidney Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in 24 hour urine protein/creatinine ratio (average of 2 values) baseline compared to 6-months in placebo vs minocycline
Secondary outcome measures
Creatinine
Change in average MACR in 24 hour urine, daytime and overnight collections (baseline vs 6 mos)
Change in urine and blood biomarkers in minocycline vs placebo treated patients at baseline vs 6 mos
Other outcome measures
Safety

Side effects data

From 2017 Phase 2 trial • 22 Patients • NCT01746043
20%
Peripheral Neuropathy
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo
Armodafinil+Minocycline
Minocycline
Armodafinil

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: MinocyclineExperimental Treatment1 Intervention
Minocycline 100 mg po bid for 6 months
Group II: PlaceboPlacebo Group1 Intervention
Placebo one tablet po bid

Find a Location

Who is running the clinical trial?

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical CenterLead Sponsor
103 Previous Clinical Trials
46,443 Total Patients Enrolled
Sharon G Adler, MDPrincipal InvestigatorLundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
~2 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top